Markets

Why Alexion Pharmaceuticals (ALXN) Could Beat Earnings Estimates Again

Looking for a stock that might be in a good position to beat earnings at its next report? Consider Alexion Pharmaceuticals, Inc.ALXN , a firm in the Medical - Biomedical and Genetics, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, ALXN has beaten estimates by at least 10% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, ALXN expected to post earnings of $1.22 per share, while it actually produced earnings of $1.38 per share, a beat of 13.1%. Meanwhile, for the most recent quarter, the company looked to deliver earnings of $1.26 per share, when it actually produced earnings of $1.56 per share instead, representing a 23.8% positive surprise.

Alexion Pharmaceuticals, Inc. Price and EPS Surprise

Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote

Thanks in part to this history, recent estimates have been moving higher for Alexion Pharmaceuticals. In fact, the Earnings ESP for ALXN is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company's earnings prospects. This is the case for ALXN, as the firm currently has a Zacks Earnings ESP of +0.21%, so another beat could be around the corner.

This is particularly true when you consider that ALXN has a great Zacks Rank #1 (Strong Buy) which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today's Zacks #1 Rank stocks here .

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that ALXN could see another beat at its next report, especially if recent trends are any guide.

New Report: An Investor's Guide to Cybersecurity

Cyberattacks have become more frequent and destructive than ever. In fact, they're expected to cause $6 trillion per year in damage by 2020. The cybersecurity industry is expanding quickly in response to these threats. In fact, a projected $170 billion per year will be spent to protect consumer and corporate assets. Zacks has just released Cybersecurity: An Investor's Guide to Locking Down Profits which reveals 4 promising investment candidates.

Download the new report now>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALXN

Other Topics

Earnings Investing Stocks